Key Market Drivers, Trends, and Forecast for the Global Organ Transplant Immunosuppressant Drugs Industry
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Organ Transplant Immunosuppressant Drugs Market Valued at Present and by 2029?
The market size for immunosuppressant drugs used in organ transplants has shown consistent growth in the recent past. It is anticipated to expand from $5.35 billion in 2024 to $5.47 billion in 2025, showcasing a compound annual growth rate (CAGR) of 2.2%. Reasons for this growth during the historical period include a rise in the number of transplant procedures, enhancements in healthcare infrastructure, advancements in research and development, the aging population worldwide, and growing awareness.
Predictions for the organ transplant immunosuppressant drugs market suggest a consistent growth trend in the coming years, with projections indicating it will reach a value of “$6.48 billion in 2029 with a compound annual growth rate (CAGR) of 4.3%.” Factors contributing to this prospective growth in the forecast period include the development of new therapies, an upsurge in organ failure cases, advancements in personalized medicine, global health campaigns and international cooperation. Other influential trends within the forecast period encompass technological innovation and improvement, strategic cost management, market consolidation and partnerships, alongside an increase in organ transplant procedures.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10143&type=smp
#What Drivers Are Influencing Growth In The Organ Transplant Immunosuppressant Drugs Market?
The organ transplant immunosuppressant drugs market is projected to grow due to the rising need for organ transplants. Organ transplants are medical procedures where a failing or diseased organ is replaced by a healthy organ from a donor, saving the recipient’s life. It is essential to have immunosuppressant drugs during such procedures to avoid organ rejection, the success of the transplant heavily relies on the availability and effectiveness of these drugs. Take for example, the Organ Procurement and Transplantation Network (OPTN), a public-private partnership based in the US, reported in 2023 that about 16,335 individuals donated one or more organs posthumously. This is the first time that the number of deceased donors has crossed 15,000, signifying a 9.6% year over year increase from 2022. Hence, the heightened demand for organ transplants is anticipated to fuel the growth of the organ transplant immunosuppressant drugs market.
The organ transplant immunosuppressant drugs market covered in this report is segmented –
1) By Drug Class: Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, Others Drug Classes
2) By Transplant Type: Heart, Kidney, Liver, Lung, Pancreas, Other Transplant Types
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Calcineurin Inhibitors: Cyclosporine, Tacrolimus
2) By Antiproliferative Agents: Azathioprine, Mycophenolate Mofetil, Mycophenolic Acid
3) By MTOR Inhibitor: Sirolimus, Everolimus
4) By Steroids: Prednisone, Methylprednisolone
5) By Other Drug Classes: Costimulation Blockers, Sodium Channel Blockers, Antibody-Based Therapies
How Are Key Trends Driving Expansion In The Organ Transplant Immunosuppressant Drugs Industry?
In the organ transplant immunosuppressant drugs market, one significant trend is product innovation. Leading companies in this market are prioritizing the development of novel solutions such as combination therapy to maintain competitiveness. The use of two or more immunosuppressant drugs in combination is gaining popularity due to its increased immunosuppression capabilities and lower risk of side effects. For example, in March 2024, Johnson & Johnson, an American pharmaceutical and biotechnology company, obtained U.S. Food and Drug Administration (FDA) approval for OPSYNVI. OPSYNVI is a single-tablet combination of tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, and macitentan, an endothelin receptor antagonist (ERA), designed for long-term management of pulmonary arterial hypertension (PAH). OPSYNVI is suitable for PAH patients who are either treatment-naïve or are currently on an ERA, PDE5 inhibitor, or both. Patients on stable doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets may also be prescribed OPSYNVI.
Which Companies Play A Key Role In The Development Of The Organ Transplant Immunosuppressant Drugs Market?
Major companies operating in the organ transplant immunosuppressant drugs market include Astellas Pharma Inc., F. Hoffmann-La Roche AG, Novartis AG, Accord Healthcare Limited, GlaxoSmithKline PLC, Pfizer Inc., Sanofi S.A., Alsachim a Shimadzu Group Company, Neovii Pharmaceuticals AG, Zydus Lifesciences Limited, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Mylan N.V., Strides Pharma Global Pte Ltd., Asahi Kasei Corporation, Bristol-Myers Squibb Company, Veloxis Pharmaceuticals A/S, Viatris Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Hansa Biopharma AB, Wockhardt Ltd, Glenmark Pharmaceuticals Ltd., Biocon Ltd., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Alkem Laboratories Limited, Torrent Pharmaceuticals Limited
What Are The Key Regional Developments Shaping The Organ Transplant Immunosuppressant Drugs Market?
North America was the largest region in the organ transplant immunosuppressant drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global organ transplant immunosuppressant drugs market report during the forecast period. The regions covered in the organ transplant immunosuppressant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10143&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
